- Home
- FSHP vs ALXO Comparison
FSHP vs ALXO Comparison
Compare FSHP & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- ALXO
- Stock Information
- Founded
- FSHP 2018
- ALXO 2015
- Country
- FSHP United States
- ALXO United States
- Employees
- FSHP N/A
- ALXO N/A
- Industry
- FSHP
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- FSHP
- ALXO Health Care
- Exchange
- FSHP NYSE
- ALXO Nasdaq
- Market Cap
- FSHP 90.3M
- ALXO 76.5M
- IPO Year
- FSHP 2024
- ALXO 2020
- Fundamental
- Price
- FSHP $10.17
- ALXO $1.74
- Analyst Decision
- FSHP
- ALXO Buy
- Analyst Count
- FSHP 0
- ALXO 6
- Target Price
- FSHP N/A
- ALXO $11.00
- AVG Volume (30 Days)
- FSHP 21.4K
- ALXO 1.1M
- Earning Date
- FSHP 01-01-0001
- ALXO 03-06-2025
- Dividend Yield
- FSHP N/A
- ALXO N/A
- EPS Growth
- FSHP N/A
- ALXO N/A
- EPS
- FSHP 0.11
- ALXO N/A
- Revenue
- FSHP N/A
- ALXO N/A
- Revenue This Year
- FSHP N/A
- ALXO N/A
- Revenue Next Year
- FSHP N/A
- ALXO N/A
- P/E Ratio
- FSHP $89.55
- ALXO N/A
- Revenue Growth
- FSHP N/A
- ALXO N/A
- 52 Week Low
- FSHP $9.99
- ALXO $1.19
- 52 Week High
- FSHP $10.20
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- ALXO 53.13
- Support Level
- FSHP N/A
- ALXO $1.56
- Resistance Level
- FSHP N/A
- ALXO $1.94
- Average True Range (ATR)
- FSHP 0.00
- ALXO 0.16
- MACD
- FSHP 0.00
- ALXO -0.01
- Stochastic Oscillator
- FSHP 0.00
- ALXO 50.00
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.